Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 27 April 2022 – At Novo Nordisk’s Annual General Meeting on 24 March 2022, it was decided to reduce the company’s B share capital from DKK 354,512,800 to DKK 348,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 6,000,000 divided into 30,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 6,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 456,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 348,512,800.
The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
|Ambre Brown Morley||+45 3079 firstname.lastname@example.org|
|Natalia Salomao Abrahao (US)||+1 848 304 email@example.com|
|Daniel Muusmann Bohsen||+45 3075 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|David Heiberg Landsted||+45 3077 firstname.lastname@example.org|
|Jacob Martin Wiborg Rode||+45 3075 email@example.com|
|Mark Joseph Root (US)||+1 848 213 firstname.lastname@example.org|
Company announcement No 31 /2022
Upcoming Life Sciences Events
- May 2022
- Pharma-Biotech Product & Company Valuation with Dr. P Frei
- June 2022
- Digital RESI
- Product & Company Valuation Course